Exact Sciences Corporation Exact Sciences Corporation

Exact Sciences Corporation

EXAS

Clasificación en acciones #1156
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Precio por acción
$104.91
Última sincronización: 2026-03-23
Capitalización bursátil
$20.03B
Cambio (1 día)
0.00%
Cambio (1 año)
67.24%
País
US
Comercio Exact Sciences Corporation (EXAS)

Categoría

Healthcare
Historial de desdoblamientos de acciones de Exact Sciences Corporation (EXAS)
La acción Exact Sciences Corporation (símbolo: EXAS) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Oct 20, 2026.
Una acción EXAS comprada antes de Oct 20, 2026 equivaldría hoy a 0 acciones EXAS.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
8 x34
US
7 x47
US
0 -
US
0 -
CN
1 x1
US